× Thanks for reading! Log in to continue. Enjoy more articles by logging in or creating a free account. No credit card required. Log in Sign up {{featured_button_text}}

The outrage was deafening.

When it was disclosed last month that EpiPen prices had more than doubled, consumers, parents, state and federal officials, and members of Congress all weighed in, and within days, America’s newest health-care villain, Mylan Pharmaceuticals, announced that it would produce a half-price generic version of the anti-allergy emergency device.

The do-it-yourself, auto-injection units filled with epinephrine are lifesaving in the infrequent episodes of allergic emergency among the estimated 3.4 million people with severe allergies.

But consider another group of patients, nearly ten times larger. Most of the nation’s 31 million diabetics need injections of insulin several times day, every day, to survive. They, too, are suffering through rampant price gouging for their life-saving drug.

“Many more patients suffer hardship from high insulin prices than EpiPen prices,” said Dr. Bruce Rector with the Drug Pricing/Value Campaign of Doctors for America.

In a recent investigation, Lee Newspapers reported that the price of insulin in the U.S. has tripled, quadrupled, and more in the last two years. One physician described an increase from $45 to $1,447 for one concentrated form of insulin since 2001.